Zomedica (ZOMDF) director granted 2,126,959 stock rights
Zomedica Corp. (ZOMDF) reported a director transaction involving stock appreciation rights.
Rhea-AI Filing Summary
Zomedica Corp. (ZOMDF) reported a director transaction involving stock appreciation rights. On 11/17/2025, the director acquired 2,126,959 stock appreciation rights with a conversion or exercise price of $0.1 per right. These rights become exercisable on 11/16/2026 and expire on 11/16/2035. Each right is linked to one share of common stock, so the transaction covers 2,126,959 underlying common shares. Following this grant, the director beneficially owns 2,126,959 derivative securities, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Appreciation Right | 2,126,959 | $0.00 | $0.00 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Zomedica (ZOMDF) report in this Form 4?
A Zomedica director reported acquiring 2,126,959 stock appreciation rights tied to the company’s common stock on 11/17/2025.
What is the exercise price of the Zomedica (ZOMDF) stock appreciation rights?
The stock appreciation rights have a conversion or exercise price of $0.1 per right.
When do the Zomedica (ZOMDF) stock appreciation rights become exercisable and when do they expire?
The rights become exercisable on 11/16/2026 and have an expiration date of 11/16/2035.
What is the director’s beneficial ownership after this Zomedica (ZOMDF) transaction?
After the reported transaction, the director beneficially owns 2,126,959 derivative securities, held in direct ownership form.
Was this Zomedica (ZOMDF) Form 4 filed for one or multiple reporting persons?
The Form 4 was indicated as filed by one reporting person, not a group.
AI-generated analysis. How Rhea-AI works. Not financial advice.